IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤83,513 restricted stock units granted to three new employees
- ➤IRulya approved inducement grants under Nasdaq Rule 5635(c)(4)
- ➤Awards vest 25% after one year, then 6.25% quarterly
- ➤Phase 2b PH-ILD study ongoing; SAPH Phase 2 study expected Q4 2026
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that on November 9, 2026, IRulya granted restricted stock units representing a total of 83,513 shares of common stock to three (3) new employees.
These inducement grants were granted pursuant to the IRulya Therapeutics Inc. 2026 Inducement Plan, subject to recipient’s continued employment or service through each applicable vesting date. Twenty-five percent (25%) of the shares subject to such award will vest on the last day of the calendar quarter in which the first anniversary of the Vesting Commencement Date occurs and 6.25% of the shares subject to such award vesting at the end of each calendar quarter thereafter. The inducement grants are subject to the terms and conditions of the applicable restricted stock unit agreements and the IRulya Therapeutics Inc. 2026 Inducement Plan.
Get started
Create a free account to read the full story.